![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Leritine |
AHFS/Drugs.com | Monograph |
Routes of administration | Tablets, injection |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | > 95% |
Metabolism | Hepatic |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H28N2O2 |
Molar mass | 352.478 g·mol−1 |
3D model (JSmol) | |
Melting point | 83 °C (181 °F) |
| |
| |
![]() ![]() |
Anileridine (trade name: Leritine) is a synthetic analgesic drug[2] and is a member of the piperidine class of analgesic agents[3] developed by Merck & Co. in the 1950s.[4] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.
Anileridine is no longer manufactured in the US or Canada.[5] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate.[6] It is also under international control per UN treaties.
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[8] It is mostly metabolized by the liver.
Inhalational | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Injection |
| ||||||||||||||
|
MOR |
|
---|---|
DOR |
|
KOR |
|
NOP |
|
Unsorted |
|
Others |
|